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ABSTRACT
We previously reported that phosphorylation of
topoisomerase (topo) IIa at serine-1106 (Ser-1106)
regulates enzyme activity and sensitivity to topo
II-targeted drugs. In this study we demonstrate
that phosphorylation of Ser-1106, which is flanked
by acidic amino acids, is regulated in vivo by casein
kinase (CK) Id and/or CKIe, but not by CKII. The
CKI inhibitors, CKI-7 and IC261, reduced Ser-1106
phosphorylation and decreased formation of etopo-
side-stabilized topo II–DNA cleavable complex. In
contrast, the CKII inhibitor, 5,6-dichlorobenzimida-
zole riboside, did not affect etoposide-stabilized
topo II–DNA cleavable complex formation. Since,
IC261 specifically targets the Ca
2+-regulated iso-
zymes, CKId and CKIe, we examined the effect of
down-regulating these enzymes on Ser-1106 phos-
phorylation. Down-regulation of these isozymes
with targeted si-RNAs led to hypophosphorylation
of the Ser-1106 containing peptide. However,
si-RNA-mediated down-regulation of CKIIa and
a’ did not alter Ser-1106 phosphorylation. Further-
more, reduced phosphorylation of Ser-1106,
observed in HRR25 (CKId/e homologous gene)-
deleted Saccharomyces cerevisiae cells trans-
formed with human topo IIa, was enhanced following
expression of human CKIe. Down-regulation of CKId
and CKIe also led to reduced formation of etopo-
side stabilized topo II–DNA cleavable complex.
These results provide strong support for an essential
role of CKId/e in phosphorylating Ser-1106 in human
topo IIa and in regulating enzyme function.
INTRODUCTION
Type II DNA topoisomerases, topoisomerase II (topo II)
a and b, regulate DNA topology by creating transient
double stranded DNA breaks (1–3). Although, both
enzymes exhibit signiﬁcant sequence homology and cata-
lyze redundant catalytic reactions, they are involved in
diﬀerent cellular functions. This diﬀerence may in part
be due to diﬀerential regulation of these enzymes.
Several diﬀerent mechanisms have been shown to regulate
topo II activity, including transcriptional, translational, as
well as post-translational mechanisms. The major post-
translational mechanisms that modulate topo II activity
are phosphorylation, interaction with other proteins and
proteasome-mediated degradation (1–3).
Both topo IIa and topo IIb are phosphorylated at
several sites, primarily in the divergent C-terminal region
(4–8). Whereas, little is known about site-speciﬁc phos-
phorylation of topo IIb, several in vitro and in vivo studies
have identiﬁed speciﬁc phosphorylation sites in topo IIa.
Within the C-terminal region of topo IIa phosphorylation
of threonine-1342, serine(Ser)-1376, Ser-1469 and Ser-
1524 catalyzed by casein kinase (CK) II (6,9–14), and of
Ser-1212, Ser-1246, Ser-1353, Ser-1360 and Ser-1392 cat-
alyzed by a proline directed kinase has been observed (15).
Recently, it has been reported that Polo-like kinase 1
phosphorylates topo IIa at Ser-1337 and Ser-1524 (16).
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ylation of Ser-29 located in the ATP binding domain
within the N-terminal region (17) and of Ser-1106 located
within the catalytic core have also been reported (18).
Whereas phosphorylation of Ser-29 is catalyzed by protein
kinase C (17), the kinase responsible for phosphorylation
of Ser-1106 has not yet been identiﬁed.
Since Ser-1106 is located in the catalytic domain of topo
IIa and phosphorylation of this site enhances enzyme
activity and sensitivity to topo II-targeted drugs in vivo
(18), it is important to decipher the mechanism by which
phosphorylation of Ser-1106 is regulated. The ﬁrst step
toward determining this mechanism would be to identify
the kinase(s) that catalyzes phosphorylation at this site.
Based on the acidic amino acid sequences that ﬂank Ser-
1106 at the amino- and carboxy-terminus, two potential
kinases that could phosphorylate this site are CKI and
CKII (19). Although CKII has been recognized as a
major kinase phosphorylating topo IIa, the role of CKI
in phosphorylating topo IIa has not been explored. Unlike
CKII, which consists of a tetramer of two catalytic sub-
units, a and/or a0, and two regulatory b subunits (20–22),
human CKI comprises of a superfamily of seven diﬀerent
isozymes that function as monomers (23,24). Structurally
these isozymes, CKIa, b, g1, g2, g3, d and e, are organized
into three distinct regions – a short N-terminal region,
a highly conserved kinase domain and a highly variable
C-terminal domain, primarily involved in regulating
enzyme function. The CKId and CKIe isozymes are very
similar in structure and exhibit 98% homology in the
kinase domain and 50% homology in the C-terminal
domain. Autophosphorylation of the C-terminal domain
leads to inhibition of the enzyme, which can be relieved
following dephosphorylation or proteolytic cleavage of
this region, often via a Ca
2+-dependent mechanism
(25,26). Indeed, it has been suggested that dephosphoryla-
tion of CKIe by the Ca
2+/calmodulin-dependent
phosphatase, calcineurin, enhances phosphorylation of
DARP-32 by this isozyme (27,28).
Our earlier studies demonstrating a Ca
2+-dependent
mechanism in regulating phosphorylation of Ser-1106
and in modulating sensitivity to topo II-targeted drugs
(18) suggested that the kinase responsible for phosphory-
lating this site may be CKId and/or CKIe, rather than
CKII. In this study we examined the role of CKId/e and
CKII in phosphorylating Ser-1106 by attenuating the
activity of these kinases with speciﬁc inhibitors or with
targeted si-RNAs. Our results demonstrated that CKId/
e, but not CKII, catalyzes the in vivo phosphorylation of
Ser-1106 and regulates topo II–DNA cleavage activity.
MATERIALS AND METHODS
Reagents
CKI-7 was obtained from Seikagaku Kogyo, Tokyo.
IC261 was kindly provided by ICOS Corp., Bothell, WA
and 5,6-dichlorobenzimidazole riboside (DRB) was pur-
chased from Calbiochem, La Jolla, CA, USA. Etoposide
was purchased from Sigma-Aldrich, St Louis, MO, USA.
Stock solutions of these compounds were made in
dimethyl sulfoxide and stored at  20
8C. The rabbit poly-
clonal antibody to topo IIa was a gift from Dr Ian
Hickson, ICRF, Oxford, UK. Mouse monoclonal antibo-
dies to CKId and CKIe were obtained from ICOS Corp.,
Bothell, WA (generous gift from Dr Anthony DiMaggio)
and BD Biosciences, San Jose, CA, USA respectively.
Goat polyclonal antibodies to CKIIa and CKIIa0 were
obtained from Santa Cruz Biotechnology, Santa Cruz,
CA, USA.
Cellculture
HL-60 cells were maintained in RPMI 1640 supplemented
with 10% fetal bovine serum and 2mM glutamine at 37
8C
in a humidiﬁed atmosphere of 5% CO2 and 95% air.
HCT-116 cells, obtained from Dr Bert Vogelstein, Johns
Hopkins University, Baltimore, MD, were maintained in
McCoy’s 5A medium supplemented with 10% fetal bovine
serum and 2mM glutamine at 37
8C in a humidiﬁed atmo-
sphere of 5% CO2 and 95% air. Cells were treated with
CKI-7 (200mM), IC261 (10mM) or DRB (40mM) for 3h.
When the combination of CKI or CKII inhibitor and
etoposide was employed, cells were pretreated with CKI-
7, IC261 or DRB for 3h. Following this treatment, cells
were washed, resuspended in inhibitor-free medium and
incubated for an additional hour in etoposide.
Transfectionwith targetedsi-RNAs
A 21-nucleotide duplex si-RNA (si-CKId/e) with the
sequence sense: 50-CUGGGGAAGAAGGGCAACCd
TdT-30 and antisense: 50-GGUUGCCCUUCUUCCCC
AGdTdT-30, purchased from Qiagen, Valencia, CA,
USA was used to target identical regions in CKId and
CKIe (29). In addition the On-Target plus SMART pool
si-RNA anti-CSNKID human (si-CKId) and On-Target
plus SMART pool si-RNA anti-CSNKIE human (si-
CKIe) were purchased from Dharmacon, Lafayette, CO.
For targeting CKIIa RNA the siGENOM SMART pool
CSNK2A1 (Dharmacon, Lafayette, CO) was employed.
The CKIIa0 si-RNA (sense: 50-CAGUCUG
AGGAGCCGCGAGdTdT-30, antisense: 50-CGGCUCC
UCAGACUGdTdT-30), previously described (30) was
synthesized by MWG Biotech, Ebersberg, Germany. The
control si-RNA (50-GCUCAGAUCAAUACGGAGAdT
dT-30) was purchased from Dharmacon, Lafayette, CO.
HCT-116 cells were incubated in serum-free McCoy’s
medium for 6–10h with the si-RNA (100nM) in the pre-
sence of Lipofectamine 2000 (Invitrogen Life Technology,
Carlsbad, CA) as described by the manufacturer. When
the combination of si-CKId and si-CKIe was employed,
the concentration of each si-RNA was reduced to 75nM.
Following the initial incubation, cells were washed and
cultured in McCoy’s medium containing 10% fetal
bovine serum and 2mM L-glutamine for 24h. At the end
of the incubation period, cells were harvested for preparing
cell lysates. When cells were transfected with si-CKId/e
about 50–70% of the cells that readily detached upon
washing were used for preparing lysates for 2D-phospho-
peptide maps of topo IIa, since both CKId and CKIe were
maximally down-regulated in this population.
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The wild-type (WT) S. cerevisiae W303 strain (ura3-1,
trp1-1, leu 2-3, 112, his3-11, 15 can1-100, ade2-1) and
7D, an HRR25D isolate isogenic to W303 (31) kindly pro-
vided by Dr Anthony DeMaggio (ICOS, Corp., Bothell,
WA) were transformed with human topo IIa cDNA
cloned in the pHT212 vector using the Yeastmaker lithium
acetate transformation system (Clontech, Palo Alto, CA).
Control transformations were carried out with the
pHT212 plasmid (LEU2). Cells transformed with the
pHT212 plasmid or pHT212 plasmid with the human
topo IIa insert were selected on plates lacking leucine
(18). The HRR25D isolate expressing human topo IIa
was transfomed with the human CKIe cDNA, (kindly
provided by Dr Jeﬀ Kuret, Ohio State University,
Columbus, OH), which was inserted in MluI and XbaI
restriction sites of the modiﬁed pRS316 plasmid,
YEpRS316. The YEpRS316 plasmid was constructed by
insertion of the ScaI fragment from pYEpWOB6 which
contains the 2mm origin. Control transformations were
carried out with the YEpRS316 plasmid (LEU2 and
URA3). The transformed cells were selected on plates
lacking leucine and uracil.
Metabolic labeling with[
32P] orthophosphoric acid
Log phase cultures of HL-60 or HCT-116 cells were incu-
bated in phosphate-free RPMI-1640 supplemented with
10% dialyzed fetal bovine serum and 2mM glutamine
for 1h at 37
8C. Cells were then labeled with carrier-free
[
32P] orthophosphoric acid (MP Biomedicals, Irvine, CA)
for an additional 3h. During the labeling period, the
CKI or CKII inhibitor was added for experiments involv-
ing these treatments. Yeast cells were labeled as previously
described (18). Brieﬂy, cells cultured overnight at 308C
with shaking (250rpm) in synthetic dropout liquid
medium lacking leucine were incubated in YPDA without
phosphate medium, for 3h with shaking, to a cell density
corresponding to 0.6 units (A600). Following centri-
fugation, cells were resuspended into 20ml of YPDA
medium without phosphate containing 5mCi of
[
32P]-orthophosphoric acid and incubated at 308C for 1h
with shaking.
Preparation ofcell lysates, immunoprecipitation
andwestern blotting
Lysates of HL-60 and HCT-116 cells were prepared
in radioimmunoprecipitation assay (RIPA) buﬀer as
described earlier (18). Topo IIa protein immuno-
precipitated from the cell lysate was subjected to SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) and
transferred to nitrocellulose membrane (18). The mem-
brane was stained with Gelcode Blue staining reagent
(Pierce Chemical Co., Rockford, IL) to visualize the
topo IIa band, which was excised and processed for pro-
teolysis with cyanogen bromide (CNBr) or trypsin (18).
For determination of down-regulation of CKId and
CKIe, western blot analysis was carried out on cell
lysates (20–40mg) prepared from si-RNA transfected
cells that were harvested just prior to labeling with
[
32P]-orthophosphoric acid (32). Cell lysate of S. cerevisiae
cells were prepared in Y-PER lysis buﬀer after freezing the
cell pellet in liquid nitrogen and human topo IIa present
in the lysate was puriﬁed by Ni
2+-nitrilotriacetic acid
essentially as described earlier (18). Puriﬁed topo IIa
was subjected to SDS–PAGE, transferred to nitrocellulose
membrane and the stained topo IIa band was processed
for phosphopetide mapping.
Phosphopeptide mapping of
32P-labeled topo IIa
The 170kDa
32P-labeled topo IIa band visualized by
staining with Gelcode Blue staining reagent on the nitro-
cellulose membrane was excised and digested with
trypsin essentially as described earlier (18). Following
extensive washing of the membrane in water, topo IIa
was proteolytically cleaved with 5mg of trypsin-TPCK
treated (Worthington Biochemical, Freehold, NJ) or
with 2mg of trypsin Gold (Promega Inc., Madison, WI)
in 1% ammonium bicarbonate, pH 8.3 at 37
8C for
14–16h. In initial experiments involving treatment with
CKI inhibitors, proteolytic digestion with TPCK-treated
trypsin consistently led to generation of two Ser-1106
containing peptides due to partial proteolysis
(Figure 1B), whereas in subsequent experiments trypsi-
nization with highly puriﬁed trypsin Gold consistently
A
B
Figure 1. CKI inhibitors, CKI-7 and IC261, decrease phosphorylation
of the topo IIa peptides containing Ser-1106. HL-60 cells were labeled
with [
32P] orthophosphoric acid for 3h at 37
8C in the absence or pre-
sence of CKI inhibitors, CKI-7 (200mM) or IC261 (10mM). Lysates of
these cells were immunoprecipitated with topo IIa-speciﬁc antibodies.
The immunoprecipitated protein was subjected to SDS–PAGE and
transferred to nitrocellulose membrane. Two-thirds of the topo
IIa band was cleaved with CNBr and one-third of the band was pro-
teolysed with trypsin. (A) CNBr fragments of topo IIa from cells trea-
ted in the absence or presence of CKI-7 or IC261 were separated
by SDS–PAGE. (B) Phosphopeptide maps of tryptic digests of topo
IIa from cells treated in the absence (Control) or presence of CKI-7 or
IC261. The phosphochromatography buﬀer, n-butanol/pyridine/acetic
acid/deionized water (5/3.3/1/4, v/v), was used for resolving peptides
in the second dimension. Arrows indicate the position of Ser-1106
containing peptides.
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The tryptic peptides released in the ammonium bicarbo-
nate solution were transferred to fresh microcentrifuge
tube and the membrane piece was washed with 100mlo f
20% acetonitrile. The pooled eluate and washings were
then concentrated by evaporation in a Savant Speed-
Vac, washed three times with water and the peptides solu-
bilized in pH 1.9 buﬀer (88% formic acid/glacial acetic
acid/deionized water, 1:3.1:36, v/v). The peptides were
then separated on thin layer cellulose plates by electro-
phoresis with pH 1.9 buﬀer in the horizontal dimension
and chromatography in the vertical dimension (33). In
initial experiments the phospho-chromatography buﬀer
contained n-butanol/pyridine/acetic acid/deionized water
(5/3.3/1/4, v/v). To improve migration of the Ser-1106-
peptide an isobutyric acid buﬀer (isobutyric acid/n-buta-
nol/pyridine/acetic acid/deionized water) (32.9/1/2.5/1.5/
14.7, v/v), which resolves extremely hydrophilic phospho-
peptides, was used.
Liquid chromatography–tandem mass
spectrometry (LC–MS)
LC–MS was carried out on tryptic digests of stained topo
IIa protein band excised from SDS–polyacrylamide gels.
In-gel trypsin digestion was carried out as described earlier
(34). Brieﬂy, following washing/destaining in two aliquots
of 50% ethanol/5% acetic acid (v/v), reduction with dithio-
threitol and alkylation with iodoacetamide, the excised gel
pieces were dried in a Speed-vac and incubated with 30ml
of 20ng/ml trypsin in 50mM ammonium bicarbonate on
ice for 10min. Any excess trypsin solution was then
removed and 20ml of 50mM ammonium bicarbonate
was added. Following overnight digestion at room tem-
perature, the peptides were extracted from polyacrylamide
pieces in two 30ml aliquots of 50% acetonitrile/5% formic
acid (v/v). These extracts were combined and evaporated
to  5ml and then reconstituted in 1% acetic acid to a total
volume of 25ml for LC–MS analysis. The tryptic peptides
in the extract (2ml/injection) were separated by reversed-
phase LC in a 10 cm 50mm (i.d.) Phenomenex Jupiter
10mm C18 self-packed capillary column using a linear gra-
dient of 2–70% acetonitrile containing 0.05M acetic acid
in 50min at a constant ﬂow rate of 0.2ml/min. The eﬄuent
was analyzed using a Finnigan LCQ-Deca ion trap mass
spectrometry system equipped with a Protana microelec-
trospray ion source (ThermoFisher, San Jose, CA) oper-
ated at 2.5kV. Data interpretation was performed with the
programs TurboSequest and Mascot. All matching spectra
were veriﬁed by manual interpretation.
Selected reaction monitoring (SRM) mode was used to
compare the extent of Ser-1106 phosphorylation in con-
trol scrambled si-RNA and si-CKId/e treated HCT-116
cells. The SRM experiment consisted of a 5-scan event
analysis in which one scan event was a standard MS
scan and the other four were diﬀerent SRM descriptors
directed to various sets of control or Ser-1106 containing
peptides, both unphosphorylated and phosphorylated. To
verify peptide recovery from the digestion procedure and
the mass spectrometry response, one ion of the trypsin
autolysis peptide VATVSLPR at m/z 422 (+2) and one
ion of the unmodiﬁed topo IIa native peptide
EVTFVPGLYK at m/z 577 (+2) were monitored. These
two descriptors served as controls. In addition, the ion
transition m/z 484 ! m/z 435 (+2) characteristic for
phosphate loss from phosphorylated Ser-29 contained in
RLpS
29VER peptide in topo IIa was monitored to con-
ﬁrm general phosphorylation of every sample. To deter-
mine the status of Ser-1106 phosphorylation, the peptide
VPDEEENEES
1106DNEKETEK containing phosphory-
lated Ser-1106 as doubly charged (m/z 1116) or triply
charged (m/z 744) ion and their corresponding unpho-
sphorylated peptide ions were monitored.
DNA cleavable complex formation
The eﬀect of etoposide on forming a stable topo II–DNA
cleavable complex was determined by measuring the
amount of precipitated protein–DNA complex and by
evaluating depletion of topo IIa not complexed with
DNA (band depletion). For measuring precipitated
protein–DNA complex, cells were labeled for 24h with
0.02–0.04 mCi/ml of [
14C]-thymidine, speciﬁc activity
53mCi/mmol (Amersham, Arlington Heights, IL). For
measuring DNA cleavable complex in cells down-
regulated for CKId plus CKIe, cells were treated for 6h
with scrambled si-RNA or si-CKId plus si-CKIe prior to
labeling. Cells were then trypsinized, treated with etopo-
side for 1h and the precipitated protein–DNA complex
was assayed as previously described (35). For the band
depletion experiment cells were treated similarly without
the addition of [
14C]-thymidine. Cell lysates were prepared
in 2-fold concentrated LDS-sample buﬀer (Invitrogen Life
Technology, Carlsbad, CA, USA). The lysates were incu-
bated at 70
8C for 10min, sonicated and centrifuged at
12000 g.Analiquot(10–15ml)ofthelysatewassubjected
to western blot analysis. The membranes were probed
with antibodies to topo IIa and topo I (internal control),
which does not form a stabilized DNA cleavable complex
withthetopoII-targeteddrug,etoposide.Down-regulation
ofCKIdandCKIewasalsodeterminedbywesternblotting
with antibodies speciﬁc for CKId and CKIe.
RESULTS
Inhibitors of CKIdand CKIe (CKI-7 andIC261) leadto
hypophosphorylation of theCNBr and tryptic topoIIa
peptides containing Ser-1106 and reduce formation of
etoposide stabilized topo II–DNA cleavable complex
The presence of acidic amino-acid residues N-terminal to
Ser-1106 and the Ca
2+-dependency of phosphorylation of
this site (18) suggested that phosphorylation of Ser-1106
may be regulated by protein kinase CKId and/or CKIe.
Therefore we ﬁrst examined whether two CKI inhibitors,
CKI-7 and IC261, speciﬁc for CKId and CKIe (36),
altered phosphorylation of Ser-1106 containing peptides.
Treatment of HL-60 cells with CKI-7 or IC261 led to
hypophosphorylation of the CNBr (peptide 34) and tryp-
tic phosphopeptides that were previously shown to harbor
Ser-1106 (Figures 1A and 1B, respectively). Comparison
of the intensity of spots corresponding to the peptides
containing Ser-1106 (normalized to two other peptides)
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decreases (20–40% and 25–30%, respectively) in phos-
phorylation of Ser-1106 as compared to untreated control
cells. To determine whether decreased phosphorylation
observed in the presence of CKI-7 or IC261 compromises
the functional activity of topo IIa, we examined the eﬀect
of CKI-7 and IC261 on formation of etoposide stabilized
topo II–DNA cleavable complex. Pre-treatment of HL-60
cells with 200mM CKI-7 or 10mM IC261 for 3h prior to
treatment with 5mM etoposide for 1h led to a signiﬁcant
(P<0.05) decrease in the formation of etoposide-stabi-
lized DNA cleavable complex (Figure 2). We also exam-
ined the eﬀect of the CKII speciﬁc inhibitor, DRB, on
formation of etoposide stabilized topo II–DNA cleavable
complex. Pretreatment with 40mM DRB did not alter eto-
poside stabilized topo II–DNA cleavable complex forma-
tion (Figure 2). These results suggest a role for CKId/e in
regulating the functional activity of topo IIa via phos-
phorylation at Ser-1106.
Down-regulation of CKIdand/or CKIe withtargeted
si-RNA decreasesphosphorylation of thetryptic peptide
containing Ser-1106
To conﬁrm the role of CKId and/or CKIe in phos-
phorylating Ser-1106 we down-regulated these two
enzymes with three diﬀerent sets of si-RNAs. These
included si-CKId/e—which targeted the nucleotide
sequence (412–430) that is identical in the CKId and
CKIe coding region; si-CKId—which is a smart pool tar-
geted to the CKId isozyme; and si-CKIe—which is a
smart pool targeted to the CKIe isozyme. The si-CKId
and si-CKIe were used individually to down-regulate the
speciﬁc isozyme or used in combination to simultaneously
down-regulate both isozymes. Since, HL-60 cells are diﬃ-
cult to transfect we used the colon carcinoma cell line,
HCT-116, for transfection of the si-RNAs. This cell line
was chosen because it can be readily transfected and the
phosphopeptide map of topo IIa in HCT-116 cells is simi-
lar to that in HL-60 cells (data not shown). Transfection
of the three si-RNAs in HCT-116 cells led to signiﬁcant
down-regulation ( 60–80%) of the targeted isozyme; si-
CKId/e and the combination of si-CKId and si-CKIe led
to down-regulation of both CKId and CKIe, whereas si-
CKId or si-CKIe when used individually, down-regulated
only the targeted enzyme CKId or CKIe, respectively
(Figures 3A, 5A and 8A). When both CKId and CKIe
were down-regulated a slight increase in the G2+M
phase of the cell cycle was observed (data not shown).
The down-regulation of CKId and CKIe in HCT-116
cells transfected with si-CKId/e resulted in signiﬁcantly
decreased (75%) phosphorylation of the tryptic Ser-1106
containing phosphopeptide, as compared to cells trans-
fected with the control scrambled si-RNA (Figure 3B).
This was not due to an increase in the G2+M population
observed in cells transfected with si-CKId/e, since phos-
phorylation at Ser-1106 was not aﬀected when cells
were blocked in mitosis following treatment with nocada-
zole (Figure 3C). Comparison of phosphorylation of
Ser-1106 in topo IIa present in cells transfected with
scrambled si-RNA or si-CKId/e by LC-MS (Figure 4)
revealed ﬁndings that were similar to those obtained
by 2D-phosphopeptide mapping. Although both phos-
phorylated and unphosphorylated Ser-1106 was detected
in control cells transfected with scrambled si-RNA, only
unphosphorylated Ser-1106 was detected in cells trans-
fected with si-CKId/e. Down-regulation of only one
isozyme, CKId or CKIe (Figure 5A), also led to hypo-
phosphorylation of the Ser-1106 containing peptide
(Figures 5B and 5C, respectively), albeit to a lesser
extent than that observed when both CKId and CKIe
were down-regulated (Figure 3B). In cells treated with
si-CKId, phosphorylation of Ser-1106 was 25–40% less
than that observed in cells treated with scrambled
si-RNA, whereas in cells treated with si-CKIe phosphor-
ylation of Ser-1106 was 40–65% less than that observed in
cells treated with scrambled si-RNA. Diﬀerential hypo-
phosphorylation of Ser-1106 in si-CKId and si-CKIe
transfected cells could be due to diﬀerences in the eﬀec-
tiveness of the two isozymes in phosphorylating this site
or due to diﬀerential down-regulation of CKId ( 60%)
and CKIe ( 80%).
To conﬁrm that phosphorylation of Ser-1106 in vivo
does not involve CKII we examined the eﬀect of transfect-
ing HCT-116 cells with si-RNAs to CKIIa and CKIIa0 on
phosphorylation of Ser-1106. Results of this experiment
revealed that transfectants, in which CKIIa and CKIIa0
were signiﬁcantly down-regulated (Figure 6A), did not
exhibit altered phosphorylation of Ser-1106 although
phosphorylation of other tryptic peptides previously
Figure 2. The CKI inhibitors, CKI-7 and IC261, but not the CKII
inhibitor, DRB, decrease formation of etoposide-stabilized topo II–
DNA cleavable complex. HL60 cells labeled overnight with
14C-thymi-
dine were pre-incubated in the absence or presence of CKI-7 (200mM),
IC261 (10mM) or DRB (40mM) for 3h at 37
8C. Cells were then
washed, resuspended in inhibitor-free medium and incubated for an
additional hour in etoposide (5mM). Control, labeled cells were incu-
bated in the presence of medium alone. The labeled DNA was preci-
pitated with SDS–KCl as described in Materials and methods section
and the dpm in the precipitate was determined by liquid scintillation
counting. DNA cleavable complex formation in the etoposide or inhi-
bitor ! etoposide treatment was determined by calculating the ratio of
dpm in treated cells to control cells.
 Signiﬁcantly (P<0.05) lower than
treatment with etoposide alone.
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reduced (Figure 6B).
Phosphorylation of Ser-1106 in human topoIIa expressedin
HRR25"S. cerevisae cells isreduced, butcan be enhanced
following transformation ofthe cellswith human CKIe
Since human topo IIa expressed in S. cerevisiae cells is
phosphorylated at Ser-1106 (18) and the S. cerevisiae
gene, HRR25 is homologous to CKId and CKIe (37),
we compared phosphorylation of Ser-1106 in WT or
HRR25 cells transformed with human topo IIa.A s
shown in Figure 7A, phosphorylation of the tryptic Ser-
1106 peptide was signiﬁcantly reduced in HRR25 cells.
Transformation of the HRR25 cells expressing human
topo IIa with human CKIe enhanced phosphorylation at
Ser-1106 (Figure 7B). This ﬁnding provides further sup-
port for the role of CKId/e, in particular the CKIe iso-
zyme, in regulating phosphorylation at Ser-1106 in
topo IIa.
Reducedphosphorylation of Ser-1106 inHCT-116 cells
transfected with si-CKIdplus si-CKIe leads to decreased
formationof etoposide stabilized topoII–DNA cleavable
complex
We previously demonstrated a functional role for Ser-1106
phosphorylation in topo IIa, based on the observation
that mutation of Ser-1106 to alanine in human topo IIa
led to decreased topo IIa function in vitro and in vivo in
JN394 yeast cells transformed with human topo IIa (18).
In this study we examined whether topo IIa function is
aﬀected when phosphorylation at Ser-1106 is altered
by down-regulating the kinase(s), CKId and/or CKIe,
involved in phosphorylating this residue. Down-regula-
tion of CKId and CKIe by si-CKId plus si-CKIe
(Figure 8A) led to a signiﬁcant (P<0.01) decrease in
SDS–KCl precipitable
14C-thymidine labeled etoposide
stabilized topo II–DNA cleavable complex (Figure 8B).
Since, formation of a stable topo IIa–DNA cleavable
complex in the presence of etoposide leads to depletion
of topo IIa not complexed with DNA, we also determined
the amount of topo IIa in lysates of control or etoposide-
treated HCT-116 cells that were transiently transfected
with scrambled si-RNA or si-CKId plus si-CKIe. In cells
transfected with si-CKId plus si-CKIe depletion of
topo IIa following treatment with etoposide was less
( 40–50%) than that observed in cells transfected with
scrambled si-RNA (Figure 8C). This ﬁnding corroborates
the previous data demonstrating decreased formation of
the etoposide stabilized topo II–DNA cleavable complex
in cells transfected with si-CKId plus si-CKIe. These
results indicate that CKId and/or CKIe are involved
in regulating topo IIa function via phosphorylation at
Ser-1106.
DISCUSSION
In the present study we identify CKId and/or CKIe as
upstream kinase(s) regulating in vivo phosphorylation of
topo IIa at Ser-1106 and thereby modulating the DNA
cleavage activity of the enzyme. The role of CKId
and/or CKIe in phosphorylating Ser-1106 is based on
several lines of experimental evidence. In vivo phosphor-
ylation of the tryptic peptide that contains Ser-1106 is
decreased when CKId and/or CKIe are inhibited by the
CKI inhibitors, CKI-7 and IC261 (speciﬁc for CKId/e), or
when CKId and CKIe are down-regulated by targeted
si-RNAs. Similarly, in human topo IIa expressing
HRR25 (CKId and CKIe homologous gene) deleted
S. cerevisiae cells, the tryptic peptide containing Ser-1106
A
B
C
Figure 3. Phosphorylation of the topo IIa peptide containing Ser-1106
is reduced in HCT-116 cells transfected with si-CKId/e, but not in
nocadazole treated cells arrested in the G2+M phase of the cell
cycle. HCT-116 cells were transfected with scrambled si-RNA or si-
CKId/e as described in Materials and methods section, or treated for
16h in the absence or presence of 200nM nocadazole. For cells trans-
fected with scrambled si-RNA or si-CKId/e a small aliquot was lysed in
RIPA buﬀer and subjected to western blot analysis to determine down-
regulation of CKId and CK1e (A). The remaining transfected cells (B),
and cells treated in the absence or presence of nocadazole (C) were
labeled with [
32P] orthophosphoric acid for 3h. At the end of the
incubation, cells were lysed in RIPA buﬀer and cell lysates were immu-
noprecipitated with topo IIa-speciﬁc antibodies. The immunoprecipi-
tated topo IIa protein was subjected to SDS–PAGE and transferred
to nitrocellulose membrane. The topo IIa band was excised, proteo-
lysed with trypsin and the labeled tryptic peptides analyzed by
2D-phosphopeptide mapping. The isobutyric acid buﬀer (isobutyric
acid/n-butanol/pyridine/acetic acid/deionized water) (32.9/1/2.5/1.5/
14.7, v/v) was used for resolving the peptides in the second dimension.
The arrow indicates the position of Ser-1106 containing peptide.
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Figure 4. Peptides containing phosphorylated Ser-1106 are not detected by LC-MS analysis of topo IIa from si-CKId/e transfected HCT-116 cells.
HCT-116 cells were transfected with scrambled si-RNA or si-CKId/e. Topo IIa protein present in these cells was puriﬁed by immunoprecipitation
and SDS–PAGE. The stained topo IIa band in the gel was digested with trypsin and the peptides were analyzed by LC–MS as described in Materials
and methods section. (A) Total ion chromatograms (upper panel) and trypsin autolysis marker at m/z 422 (lower panel) of topo IIa tryptic digests
from cells transfected with scrambled si-RNA or si-CKId/e.( B) SRM chromatograms for the doubly charged peptide ion containing phosphorylated
Ser-1106at m/z 1116 (upper panel) and CID spectrum of doubly charged peptide ion (lower panel) containing phosphorylated Ser-1106 in topo IIa,
detected only in samples treated with scrambled si-RNA. (C) SRM chromatograms for the triply charged peptide ion containing phosphorylated
Ser-1106at m/z 744 (upper panel) and characteristic H3PO4 neutral loss for the m/z 744 (+3) phosphorylated peptide (middle panel). CID spectrum
of triply charged peptide ion (lower panel) containing phosphorylated Ser-1106 in topo IIa was detected only in samples treated with scrambled si-
RNA. Characteristic loss of H3PO4 is seen in both CID spectra. Detected b (N-terminal) and y (C-terminal) fragment ions are labeled in the spectra.
388 Nucleic Acids Research, 2009, Vol. 37, No. 2is also hypophosphorylated, and phosphorylation at this
site can be enhanced following transformation of these
cells with human CKIe. The decrease in phosphorylation
of the Ser-1106 tryptic peptide is indeed due to reduced
phosphorylation at this site, since our earlier studies
indicated that in vivo phosphorylation of this tryptic
peptide was not observed when Ser-1106 in topo IIa was
mutated to alanine (18). Furthermore, LC–MS analysis
of phosphorylated Ser-1106 in topo IIa obtained from
HCT-116 cells treated with scrambled si-RNA or
si-CKId/e revealed the presence of phosphorylated
Ser-1106 only in scrambled si-RNA treated cells.
The decrease in phosphorylation at Ser-1106 observed
in cells exhibiting reduced kinase activity of CKId and
CKIe correlates with a decrease in topo IIa function.
Inhibition of the CKI activity in cells treated with CKI
inhibitors, CKI-7 or IC-261 leads to reduced formation of
topo II–drug DNA complex in vivo. Similarly, when CKId
and CKIe are down-regulated by targeted si-RNAs, for-
mation of the etoposide stabilized topo II–DNA cleavable
complex is reduced. These results indicate that the phos-
phorylation at Ser-1106 catalyzed by CKId and/or CKIe
enhances the in vivo DNA cleavage activity of topo IIa.
Several diﬀerent kinases, including CKII, protein kinase
C, proline directed kinases e.g. cdc2 and Polo-like kinase 1
have been reported to phosphorylate topo IIa (6,9–17).
However, this is the ﬁrst report demonstrating CKI as a
physiologically relevant kinase that modulates phosphor-
ylation and activity of topo IIa. Our data demonstrating
decreased phosphorylation of several peptides (excluding
the Ser-1106 containing peptide) following down-
regulation of CKIIa and CKIIa0 with targeted si-RNAs
provides evidence that CKII is also capable of
′
ε
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Figure 5. Down-regulation of CKId or CK1e with targeted si-RNAs in
HCT-116 cells decreases phosphorylation of the topo IIa peptide con-
taining Ser-1106. HCT-116 cells were transfected with scrambled
si-RNA, si-CKId or si-CKIe as described in Materials and methods
section. A small aliquot of the cells was lysed in RIPA buﬀer and
subjected to western blot analysis to determine down-regulation of
CKId and CKIe (A). The remaining cells were labeled with [
32P] ortho-
phosphoric acid for 3h, lysed in RIPA buﬀer and the cell lysates were
immunoprecipitated with topo IIa-speciﬁc antibodies. The immunopre-
cipitated topo IIa protein was subjected to SDS–PAGE and transferred
to nitrocellulose membrane. The stained topo IIa band was excised,
proteolysed with trypsin and the labeled tryptic peptides analyzed by
2D-phosphopeptide mapping (B, C). The isobutyric acid buﬀer (isobu-
tyric acid/n-butanol/pyridine/acetic acid/deionized water) (32.9/1/2.5/
1.5/14.7, v/v) was used for resolving the peptides in the second dimen-
sion. The arrow indicates the position of Ser-1106 containing peptide.
′
A
B ′
Figure 6. Down-regulation of CKIIa and a0 with targeted si-RNAs
does not alter phosphorylation of the topo IIa peptide containing
Ser-1106. An aliquot of HCT-116 cells transfected with scrambled
si-RNA or si-CKIIa plus si-CKIIa0, as described in Materials and
methods section, were lysed in RIPA buﬀer and subjected to western
blot analysis to determine down-regulation of CKIIa and CKIIa0 (A).
The remaining cells were labeled with [
32P] orthophosphoric acid for
3h. Cell lysates prepared in RIPA buﬀer were immunoprecipitated with
topo IIa-speciﬁc antibodies, subjected to SDS–PAGE and transferred
to nitrocellulose membrane. The stained topo IIa band was excised,
proteolysed with trypsin and the labeled tryptic peptides analyzed by
2D-phosphopeptide mapping (B). The isobutyric acid buﬀer (isobutyric
acid/n-butanol/pyridine/acetic acid/deionized water) (32.9/1/2.5/1.5/
14.7, v/v) was used for resolving the peptides in the second dimension.
The arrow indicates the position of Ser-1106 containing peptide.
Nucleic Acids Research,2009, Vol. 37,No. 2 389phosphorylating topo IIa in vivo. However, phosphoryla-
tion at CKII sites does not signiﬁcantly aﬀect sensitivity to
topoII-targeted drugs, since treatment of HL-60 cells with
the CKII inhibitor, DRB, did not signiﬁcantly alter for-
mation of topo II-drug–DNA complex in vivo. Since our
study did not evaluate the eﬀect of reduced phosphoryla-
tion at CKII sites on other functions of topo IIa, the
functional role of phosphorylations at CKII sites remains
unclear. It is possible that phosphorylation at CKII sites,
most of which map to regions in the C-terminal domain,
along with other phosphorylations within this region reg-
ulate accessibility of the catalytic site to its substrate. This
mechanism would be analogous to that described for
regulation of the activity of CKId and CKIe, wherein
dephosphorylation of the C-terminal region activates the
enzyme.
Our previous data demonstrating Ca
2+-dependent
phosphorylation of Ser-1106 (18), provides further sup-
port for the role of CKId and/or CKIe (Ca
2+-regulatable
enzymes), but not CKII, as physiologic kinases that mod-
ulate Ser-1106 phosphorylation. Although, the catalytic
activity of CKId and CKIe does not require Ca
2+, these
enzymes can be regulated via Ca
2+-dependent depho-
sphorylation or proteolysis (25,26). In neostriatal neurons,
the metabotrophic glutamate receptors activate CKIe by
dephosphorylating the inhibitory C-terminal autopho-
sphorylation sites by the Ca
2+-dependent phosphatase,
calcineurin (38). The activated CKIe then leads to phos-
phorylation of Ser-137 of DARPP-32. A scenario similar
to that described in neostriatal muscles, could explain
how phosphorylation of Ser-1106 is regulated by Ca
2+.
Dephosphorylation by calcineurin and subsequent activ-
ation of CKId and/or CKIe could result in phosphoryla-
tion of Ser-1106. Alternatively, a Ca
2+-dependent
protease, e.g. calpain, which is activated by calcium
inﬂux in neurons (27,39), could remove the inhibitory
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Figure 8. Down-regulation of CKId and CKIe in HCT-116 cells leads
to reduced topo IIa–DNA cleavage activity. HCT-116 cells were treated
with scrambled si-CKId (75nM) plus si-CKIe (75nM) as described in
Materials and methods section and subsequently treated with etoposide
for 1h. An aliquot of the cell lysate was used to determine down
regulation of CKId and CKIe (A). Cells labeled with [
14C] thymidine
were lysed and precipitated with SDS–KCl. The dpm present in the
precipitate was determined by liquid scintillation counting (B).
 Signiﬁcantly (P<0.01) lower than scrambled si-RNA-treated cells.
Band depletion of topo IIa not present in the etoposide–stabilized
DNA complex was determined by western blotting of lysates prepared
in 2-fold concentrated LDS-sample buﬀer (C). The amount of topo IIa
was normalized with topo I, which does not form a stable complex with
the topo II-targeted drug, etoposide.
A
B
Figure 7. Phosphorylation of Ser-1106 in human topo IIa expressing
HRR25 S. cerevisae cells is reduced, but can be enhanced following
transformation of the cells with human CKIe. WT W303 cells or
HRR25 isolate isogenic to W303 cells transformed with human
topo IIa (A), or topo IIa expressing HRR25 W303 cells transformed
with vector control or human CKIe cDNA (B) were labeled with [
32P]
orthophosphoric acid for 1h as described in Materials and methods
section. Topo IIa from cell lysates prepared in Y-PER lysis buﬀer
was puriﬁed by Ni
2+-nitrilotriacetic acid or immunoprecipitated with
topo IIa antibody. Puriﬁed topo IIa was subjected to SDS–PAGE and
transferred to nitrocellulose membrane. The stained topo IIa band was
excised, proteolysed with trypsin and the labeled tryptic peptides
analyzed by 2D-phosphopeptide mapping. The phosphochromatogra-
phy buﬀer, n-butanol/pyridine/acetic acid/deionized water (5/3.3/1/4,
v/v), was used for separating the peptides in the second dimension
(A) and the isobutyric acid buﬀer (isobutyric acid/n-butanol/pyridine/
acetic acid/deionized water) (32.9/1/2.5/1.5/14.7, v/v) was used for
resolving the peptides in the second dimension (B). The arrow indicates
the position of Ser-1106 containing peptide.
390 Nucleic Acids Research, 2009, Vol. 37, No. 2domain in CKId or CKIe and lead to activation of these
kinases.
CKI isozymes are involved in regulating several diﬀer-
ent cellular processes (40). The CKId and CKIe isozymes
have been shown to modulate the development process
because of their role in the wnt signaling pathway.
In addition, these isozymes play a role in circadian
rhythm, cell division, apoptosis and neurodegenerative
diseases. CKId and CKIe phosphorylate p53, tubulin
and microtubule-associated proteins to regulate cell
growth, chromosome segregation and stress response at
the spindle apparatus and the mitotic centrosome. The
identiﬁcation of topo IIa, which is also involved in regu-
lating DNA replication and cell division, chromosome
segregation and DNA repair, as another nuclear substrate
of CKId and/or CKIe in this study, suggests that these
CKI isozymes may be essential for regulating various
aspects of DNA metabolism. In this regard, topo IIa
could function as part of a protein complex that comprises
of transcription factors, nuclear regulatory proteins and
kinases (including CKId and/or CKIe)/phosphatases that
regulate phosphorylation/dephosphorylation of compo-
nents of the complex. Thus, it would be important to
determine whether CKId or CKIe is capable of associating
with topo IIa.
In summary our results demonstrate that CKId and/or
CKIe are physiologically relevant kinase(s) that are
involved in regulating site-speciﬁc phosphorylation at
Ser-1106 and modulating the function of topo IIa. Since
Ser-1106 phosphorylation regulates sensitivity of cells to
topo II-targeted drugs and expression of CKId and/or
CKIe can be altered in cancer cells, one potential mecha-
nism by which tumor cells develop resistance to topo
II-targeted drugs could involve decrease in expression or
activation of CKId and/or CKIe. The correlation of
Ser-1106 hypophosphorylation with etoposide resistance
was not only observed in cell culture model systems
but was also seen in blast cells isolated from patients
with acute myelogenous leukemia. Comparison of
Ser-1106 phosphorylation with etoposide induced apopto-
sis revealed that reduced phosphorylation at Ser-1106 was
associated with decreased apoptosis (data not shown).
Thus, it might be possible to identify sensitivity of
tumors to topo IIa-targeting drugs by characterizing
phosphorylation at Ser-1106 or by determining the expres-
sion level or activity of CKId and CKIe in tumor samples.
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